drug free News
-
Study Suggests Futura’s Drug-Free Erectile Dysfunction Gel Suitable For US OTC Pathway
Futura article in HBW: Study Suggests Futura’s Drug-Free Erectile Dysfunction Gel Suitable For US OTC ...
-
Introducing the Latest FFRangio System - Video Highlight from Dr. Rahul Sharma’s CVIT Webinar
The latest CathWorks FFRangio System delivers wire-free and drug-free 3D FFR guidance that is practical for every case. In this video highlight from CVIT Japan 2021, Dr. Rahul P. Sharma, MBBS, FRACP, Director of Structural Interventions at Stanford Medical Center, gives a “live” view of the software interface and details the essential information depicted on screen, including: ...
By CathWorks
-
4 Drug-Free Tips to Outsmart a Migraine this 4th of July
Cefaly® the first device of its kind to receive U.S. Food and Drug Administration (FDA) approval for the preventive treatment of migraine headaches wants all migraineurs to enjoy a safe, and migraine-free, 4th of July. “A terrible migraine can dampen any holiday,” says Dr. Mark Harman, US Medical Director with CEFALY Technology. “We’d like any fogginess this ...
By CEFALY
-
How Does FFRangio Work? - Insights from Dr. Rahul Sharma’s CVIT 2021 Presentation
FFRangio is a non-invasive, angiography-based system that provides quick, wire-free, and drug-free assessment of FFR for multiple vessels. In this video highlight from CVIT Japan 2021, Dr. Rahul P. Sharma, MBBS, FRACP, Director of Structural Interventions at Stanford Medical Center, gives an overview of how FFRangio works. Topics include: 3D model reconstruction – including 3D ...
By CathWorks
-
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. "We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital ...
-
The Irish News - Latest cash injection sees medical tech firm Neurovalens target US growth
Neurovalens has been boosted by £750,000 from the Growth Finance Fund to support the launch of a new sleep product in the USA later this year. In September the company, founded by Dr Jason McKeown in 2015 and which has already secured £4.6 million from a number of equity investors, was offered £1 million from Invest NI for its new research and development programme in a move ...
-
CathWorks and Quest International Announce Global Post-Sales Technical Service Support Partnership
CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support of CathWorks’ fast-growing install-base of customers globally. CathWorks ...
By CathWorks
-
FDA Approves Theranica`s Nerivio® for Acute Treatment of Migraine in Adolescents
Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the ...
-
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning a new HCPCS Level II code K1023 "Distal Transcutaneous Electrical Nerve Stimulator, Stimulates ...
-
KiOmed Pharma appoints seasoned industry executives and expands its board of directors
KiOmed Pharma announces the appointment of two seasoned biotech executives: Dr Pierre Rigaux, MD, PhD is joining its Board of Directors, and Dr Mathias Schifflers, MD is appointed Chief Medical Officer and joins its executive management team “We are absolutely delighted to announce the appointment of Dr Pierre Rigaux to our Board of Directors. Pierre is an extremely well-regarded executive ...
-
FDA-Approved Cefaly Device to Stop Migraines Now Available
Renowned for helping prevent migraine attacks, a new FDA clearance paves way for more Cefaly devices that can now stop a migraine in progress and prevent a future episode too. CEFALY Technology announces today the release of two new U.S. Food and Drug Administration (FDA)-cleared migraine treatment devices. Cefaly®, already the first FDA-approved external trigeminal nerve stimulation (e-TNS) ...
By CEFALY
-
Excite Medical participates in successful trade mission to Ecuador
Excite Medical, the maker of the revolutionary DRX9000™ spinal decompression machine, participated in a successful trade mission to Quito, Ecuador April 4–7, facilitated by Enterprise Florida. “It was an honor to participate in this trade mission to Ecuador, meet leaders and executives, and help spread the word about non-surgical, drug-free treatments for low back pain,” ...
-
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio in Patients with Chronic Migraine
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute ...
-
CathWorks FFRangio System outcomes study to be presented at ACC 2022
CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC. Dr. Witberg and his co-investigators in Israel and Japan examined the 1-year clinical outcomes of ...
By CathWorks
-
National drug “take back” program offered in New England communities on Sat. Sept. 25 (CT, ME, MA, NH, RI, VT)
This Saturday, Sept. 25, New Englanders will have the opportunity to safely dispose of unused and unwanted medicines from their homes. On Saturday, more than 3400 sites nationwide will take part in the U.S. Drug Enforcement Administration’s "Take Back" campaign. This is a collaborative effort with state and local government, community, public health and law enforcement partners to collect ...
-
Neurolief Announces Positive Results From RIME Clinical Study of Its Brain Neuromodulation System for Treating Acute Migraine
Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. The study met all its endpoints with statistical significance. “The results of this study are extremely promising for those seeking an ...
-
Portal Instruments appoints Dr. Veena Rao, PhD, as Chief Business Officer
Portal Instruments is pleased to announce the appointment of Dr. Veena Rao, PhD, as Chief Business Officer, effective December 5th, 2022. Dr. Rao will lead the identification, evaluation, and negotiation of partnership opportunities for Portal. In addition, Dr. Rao, in close collaboration with the CEO and cross-functional team, will guide the company’s short and long-term commercial ...
-
CD Formulation Unveils Hydrogel Microneedle Patch Technology to Increase Drug Loading Capacity
CD Formulation, a leading pharmaceutical contract service company, has recently unveiled groundbreaking hydrogel microneedle patch technology aiming at increase the drug loading capacity and enhance drug delivery efficiency. The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles ...
-
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus ...
-
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the "Agreement") for Bentrio™ with Wellesta Holding Pte Ltd ("Wellesta") has been expanded. In addition to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you